Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
In: Business Wire (English), 2020-06-12
Online
Zeitungsartikel
Zugriff:
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced preliminary results from the fully enrolled ALX148 plus rituximab combination cohort of the Phase 1 clinical program at the 25th Annual Congress of EHA [abstract #EP1247]. As of April 1, 2020, 33 patients with relapsed or refractory non-Hodgkin Lymphoma (NHL) were administered ALX148 at 10 or 15 mg/kg once per week (QW) in combination with a standard rituximab regimen. The following key results were observed in response-evaluable subjects: ALX148 in combination with a standard regimen of rituximab is well tolerated with no maximum tolerated dose reached. The maximum administered dose is 15 mg/kg QW (molar equivalent to 30 mg/kg QW an antibody) with no exposure-dependent cytopenia observed across the exposure range evaluated. ALX148 10mg/kg plus rituximab (n=22): In all subjects, an overall objective response rate (ORR) of 40.9% and median progression-free survival (mPFS) of 7.4 months were observed.In patients with aggressive NHL (n=15) an ORR of 33.3% and median duration of response (mDOR) of 5.6 months were observed.In patients with indolent NHL (n=7) an ORR of 57.1% was observed and mDOR was not reached.Three patients achieved complete response. ALX148 15mg/kg plus rituximab (n=11): In all subjects, an ORR of 54.6% was observed and mPFS was not reached.In patients with aggressive NHL (n=7) an ORR of 42.9% was observed and mDOR was not reached.In patients with indolent NHL (n=4) an ORR of 75% was observed and mDOR was not reached.Two patients achieved complete response. ALX148 demonstrates linear pharmacokinetics at 10 mg/kg and 15 mg/kg QW with near complete peripheral CD47 target occupancy in combination with rituximab at both dose levels. [ABSTRACT FROM PUBLISHER]
Titel: |
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
|
---|---|
Autor/in / Beteiligte Person: | ALX Oncology Holdings Inc. |
Zeitschrift: | Business Wire (English), 2020-06-12 |
Veröffentlichung: | 2020 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|